Radboud University Medical Center Increases HiFi Sequencing Capacity with PacBio’s Sequel IIe
January 07, 2022 09:00 ET
|
Pacific Biosciences of California, Inc.
MENLO PARK, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced Radboud University Medical...
PacBio and Care4Rare Consortium Collaborate on Rare Disease Research Study
January 05, 2022 09:00 ET
|
Pacific Biosciences of California, Inc.
MENLO PARK, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- PacBio, a leading provider of high-quality, long-read sequencing platforms, and the Care4Rare Canada Consortium (Care4Rare) announce today they...
CENTOGENE’s CentoCloud® Set to Revolutionize Rare Disease Diagnostics With Decentralized SaaS Platform for Laboratories Around the World
January 04, 2022 08:00 ET
|
Centogene NV
The CentoCloud solution is a cloud-based Software as a Service (SaaS) platform that enables laboratories around the world to analyze, interpret, and report genomic variants, and will be able to...
PacBio and UCLA Health Announce Research Collaboration for Whole Genome Sequencing in Rare Diseases
December 07, 2021 09:00 ET
|
Pacific Biosciences of California, Inc.
MENLO PARK, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate sequencing platforms, and the UCLA Institute for Precision Health and...
PacBio and ARUP Laboratories Collaborate in a Study to Improve Rare Disease Diagnosis
November 18, 2021 09:00 ET
|
Pacific Biosciences of California, Inc.
MENLO PARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, and ARUP Laboratories announced today they are...
CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases
November 04, 2021 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Enrolls First Patient in Frontotemporal Dementia (FTD) Clinical Study
October 28, 2021 06:30 ET
|
Centogene NV
FTD is a rapidly progressing neurodegenerative disease; up to 30% of all cases worldwide caused by genetic mutations, including the progranulin gene mutation (FTD-GRN)Study will enroll and genetically...
CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases
October 06, 2021 08:00 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage Company focused on generating...
LEXEO Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies for Rare and Non-Rare Monogenic Diseases
January 07, 2021 07:30 ET
|
LEXEO Therapeutics
Rare disease and gene therapy industry veterans Steven Altschuler, M.D., R. Nolan Townsend and Jay Barth, M.D., team up with gene therapy pioneer Ronald Crystal, M.D., to launch fully integrated gene...
CENTOGENE Expands Partnership with PTC Therapeutics to Generate New Insights for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency
November 25, 2020 06:30 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and HEIDELBERG, Germany and BERLIN, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that...